NASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free QNRX Stock Alerts $0.64 +0.01 (+1.59%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.60▼$0.6550-Day Range$0.63▼$2.9052-Week Range$0.60▼$12.00Volume56,890 shsAverage Volume72,843 shsMarket Capitalization$2.35 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Quoin Pharmaceuticals alerts: Email Address Quoin Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside527.5% Upside$4.00 Price TargetShort InterestHealthy0.42% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.21 out of 5 stars 3.5 Analyst's Opinion Consensus RatingQuoin Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageQuoin Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.42% of the outstanding shares of Quoin Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently increased by 31.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldQuoin Pharmaceuticals does not currently pay a dividend.Dividend GrowthQuoin Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QNRX. Previous Next 0.6 News and Social Media Coverage News SentimentQuoin Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Quoin Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 4 people have searched for QNRX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quoin Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Quoin Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 8.63% of the stock of Quoin Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Quoin Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quoin Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuoin Pharmaceuticals has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Quoin Pharmaceuticals Stock (NASDAQ:QNRX)Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Read More QNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QNRX Stock News HeadlinesApril 19, 2024 | americanbankingnews.comQuoin Pharmaceuticals (NASDAQ:QNRX) Shares Down 1.8% March 16, 2024 | seekingalpha.comQuoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call TranscriptApril 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 15, 2024 | markets.businessinsider.comMaxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To KnowMarch 15, 2024 | finance.yahoo.comQuoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finanznachrichten.deQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsMarch 14, 2024 | benzinga.comQuoin Pharmaceuticals: Q4 Earnings InsightsMarch 13, 2024 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsApril 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 7, 2024 | msn.comWhy Quoin Pharmaceuticals (QNRX) Shares Are NosedivingMarch 7, 2024 | globenewswire.comQuoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ETMarch 6, 2024 | finance.yahoo.comQNRX: Potential Pool of Study Participants Expands; Financial Position StrengthsMarch 5, 2024 | seekingalpha.comQTI, RNLX and MTC among pre-market losersMarch 5, 2024 | msn.comWhy Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?March 5, 2024 | finance.yahoo.comQuoin Pharmaceuticals Announces Pricing of $6.5 Million Public OfferingMarch 4, 2024 | marketwatch.comQuoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 TrialMarch 4, 2024 | markets.businessinsider.comQuoin Pharma Says FDA Clears Recruitment Of Teen Subjects For Two Ongoing Clinical Trials For QRX003March 4, 2024 | msn.comWhy Quoin Pharmaceutical Stock Is SoaringDecember 15, 2023 | markets.businessinsider.comBuy Rating for Quoin Pharmaceuticals Amid Promising Netherton Syndrome Drug ProspectsDecember 13, 2023 | morningstar.comQuoin Pharmaceuticals Ltd ADRDecember 13, 2023 | finanznachrichten.deQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton SyndromeDecember 13, 2023 | markets.businessinsider.comFDA Clears Quoin Pharma's Protocol Amendments For QRX003 Trials In Netherton Syndrome TreatmentNovember 13, 2023 | finance.yahoo.comQNRX: Planned Protocol Modifications Might Accelerate QRX003 Regulatory ApprovalNovember 10, 2023 | finance.yahoo.comQuoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | morningstar.comQuoin Pharmaceuticals Ltd ADR QNRXNovember 9, 2023 | msn.comQuoin Pharmaceuticals GAAP EPS of -$7.61 misses by $4.89November 8, 2023 | finance.yahoo.comQuoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial ResultsSee More Headlines Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/27/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:QNRX CUSIPN/A CIK1671502 Webquoinpharma.com Phone(703) 980-4182Fax972-9767-8750Employees4Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+527.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($10.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-105.09% Return on Assets-55.69% Debt Debt-to-Equity RatioN/A Current Ratio3.15 Quick Ratio3.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.74 per share Price / Book0.11Miscellaneous Outstanding Shares3,686,000Free Float3,564,000Market Cap$2.35 million OptionableNot Optionable Beta1.81 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Michael Myers Ph.D. (Age 62)Co-Founder, CEO & Chairman Comp: $661.8kMs. Denise Carter (Age 55)Co-Founder, COO & Director Comp: $537.8kMr. Gordon Bruce Dunn J.D. (Age 60)Chief Financial Officer Comp: $523.38kKey CompetitorsDynatronicsNASDAQ:DYNTTenon MedicalNASDAQ:TNONReShape LifesciencesNASDAQ:RSLSNemaura MedicalNASDAQ:NMRDProSomnusNASDAQ:OSAPView All Competitors QNRX Stock Analysis - Frequently Asked Questions Should I buy or sell Quoin Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QNRX shares. View QNRX analyst ratings or view top-rated stocks. What is Quoin Pharmaceuticals' stock price target for 2024? 1 equities research analysts have issued 12-month price objectives for Quoin Pharmaceuticals' stock. Their QNRX share price targets range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 527.5% from the stock's current price. View analysts price targets for QNRX or view top-rated stocks among Wall Street analysts. How have QNRX shares performed in 2024? Quoin Pharmaceuticals' stock was trading at $4.91 at the beginning of 2024. Since then, QNRX stock has decreased by 87.0% and is now trading at $0.6375. View the best growth stocks for 2024 here. Are investors shorting Quoin Pharmaceuticals? Quoin Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 15,300 shares, an increase of 31.9% from the March 31st total of 11,600 shares. Based on an average trading volume of 596,100 shares, the short-interest ratio is currently 0.0 days. View Quoin Pharmaceuticals' Short Interest. When is Quoin Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our QNRX earnings forecast. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) announced its quarterly earnings data on Wednesday, March, 13th. The company reported ($2.08) EPS for the quarter, beating analysts' consensus estimates of ($2.37) by $0.29. When did Quoin Pharmaceuticals' stock split? Quoin Pharmaceuticals's stock reverse split on Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QNRX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
